

Metreleptin for treating lipodystrophy

Information for the public

Published: 24 February 2021

www.nice.org.uk

Metreleptin (Myalepta) is available on the NHS as a possible treatment for the complications of leptin deficiency in:

- generalised lipodystrophy in people who are 2 years and over
- partial lipodystrophy in people who are 12 years and over when metabolic control is inadequate despite standard treatments, but only if HbA1c levels are above 58 mmol/mol (7.5%), fasting triglycerides are above 5.0 mmol/litre, or both.

If you are not eligible for metreleptin but are already taking it, you should be able to continue until you and your doctor decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

These organisations can give you advice and support:

- [Lipodystrophy UK](#), lipodystrophyuk@hotmail.com
- [Diabetes UK](#), 0345 123 2399

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-3473-7